<DOC>
	<DOCNO>NCT00826969</DOCNO>
	<brief_summary>The study objective investigate placebo-controlled , double-blind manner effect inhale corticosteroid ( ciclesonide ) airway hyperresponsiveness measure PD15 mannitol . Treatment medication administer follow : 320 microgram ciclesonide placebo inhale daily . The study duration consist treatment period 4 week . The study provide data safety ciclesonide .</brief_summary>
	<brief_title>Ciclesonide Treatment Airway Hyperresponsiveness</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Respiratory Hypersensitivity</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>1 . Referred pulmonology department university hospital Basel suspect asthma define respiratory symptom like wheeze cough chest tightness . 2 . Asthma symptom partly control accord GINA ( October 2006 ) 1 week prior randomization 3 . FEV1 ≥ 70 % predict 4 . 18 70 year old 1 . Smoker exsmoker &gt; 10 pack year 2 . COPD 3 . Upper respiratory tract infection within past 4 week . 4 . ICS oral steroid previous month inclusion 5. bblockers within past 4 week 6 . Current treatment medication define section concomitant medication ( ICS study medication , ßblockers ) 7 . Pregnancy 8 . Known malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ciclesonide</keyword>
</DOC>